Clinical-stage biotech Kalohexis seeks public listing to advance therapies targeting obesity and cancer cachexia via melanocortin system modulation.
Kalohexis has confidentially filed for an initial public offering (IPO) with the US Securities and Exchange Commission, aiming to raise capital for its metabolic disorder pipeline. The company has not disclosed share count or pricing details for its potential debut on public markets in 2026.
The biotech, spun out from Endevica Bio in March 2026, focuses on therapies for obesity and cancer cachexia. Its lead asset, mifomelatide, a dual MC3R/MC4R agonist, is in Phase II trials for cancer cachexia in advanced disease patients. Kalohexis targets the melanocortin system to regulate appetite and inflammation, addressing conditions with limited FDA-approved treatments.